Table 1.
Features of HPV-positive patients enrolled in the randomized study
| Number of partecipans | 160 |
| Nullipara | 60/160 (37.5%) |
| Pluripara | 100/160 (62.5%) |
| Monogamous heterosexual relationships | 124/160 (77.5%) |
| Same-sex relationships | 36/160 (22.5%) |
| Smoking | 72/160 (45%) |
| Contraceptive pill use | 38/160 (23.75%) |
| Symtoms of vaginosis | 43/160 (26.8%) |
| Age (median-years) | 45 (30–64) |
| Patients with high-risk HPV | 105/160 (65%) |
| High HPV genotype | HPV 16: 29/105 (27.6%) |
| HPV 18: 17/105 (16.1%) | |
| HPV 66: 13/105 (12.3%) | |
| HPV 68: 15/105 (14.2%) | |
| HPV 58: 10/105 (9.5%) | |
| HPV 45: 18/105 (17.1%) | |
| HPV 53: 12/105 (11.4%) | |
| HPV 51: 18/105 (17.1%) | |
| HPV 52: 17/105 (16.1%) | |
| HPV 35: 18/105 (17.1%) | |
| Patients with concomitant Low risk HPV | 55/160 (34%) |
| Low HPV genotype | HPV 6: 23/55 (41%) |
| HPV 11: 29/55 (52.7%) | |
| HPV 40: 3/55 (5.3%) |